Raymond James raises Corpay stock price target on growth outlook

Raymond James raised Corpay’s price target to $390 from $361 while reiterating an Outperform rating, implying upside from the current $331 share price. The firm sees modest first-quarter revenue and EPS upside from stronger organic Corporate Payments growth, and lifted fiscal 2026 estimates slightly even after factoring in the $75 million revenue hit from the PayByPhone divestiture. Corpay also remains on track for mid-teens organic revenue growth over the medium term, with the stock trading at 21.82x P/E and about 11x 2027 estimated EPS.

Analysis

The setup is less about the headline target hike and more about the quality of the forward revision: management is using divestiture drag to re-center the mix toward higher-ROIC payments rather than chasing top-line optics. That matters because the market typically underwrites CPAY on durable organic growth plus margin resiliency, so a clean mix shift can support multiple expansion even if reported revenue growth looks mechanically softer for a few quarters.

Second-order beneficiary is not just CPAY itself but the broader fintech/payments complex that can demonstrate pricing power through FX and fuel-linked pass-throughs. If fuel spreads continue to neutralize commodity volatility, investors may start treating the business like a quasi-inflation hedge, which supports valuation stability in a tape that is otherwise rewarding quality compounders. The risk is that consensus may be too comfortable extrapolating mid-teens organic growth into 2026-27 without fully discounting slower SMB travel activity or a corporate spend pullback.

The near-term catalyst stack is asymmetric: the next earnings print and the corporate payments presentation are both vehicles for management to re-affirm the mix shift and normalize post-divestiture guidance. If they merely confirm the current trajectory, the stock can grind higher because the current multiple still leaves room for a re-rate versus higher-quality payments peers; if they disappoint on organic growth or FX, the downside is likely driven by multiple compression rather than estimate cuts. The key watch item is whether the market starts valuing CPAY on 2027 EPS too early, which would cap upside if investors decide the growth profile is already fully recognized.

Contrarian view: the target increase may actually be a signal that the easy money has been made, not that the story is inflecting. With valuation already converging toward fair value and the stock trading off a forward multiple that embeds solid execution, the more attractive expression may be relative value rather than outright long exposure. In other words, the upside case is real, but it is increasingly a “show-me” setup where one clean quarter matters more than the research note itself.

Key Decisions for Investors

• Stay long CPAY into earnings only if size is modest; target a 6-8% upside move into the May print, but cut quickly on any organic growth miss because the stock is now sensitive to multiple compression.
• Pair trade: long CPAY / short a lower-quality payments or fintech compounder with more leverage to transaction volumes over the next 1-2 quarters; favor the leg with better margin durability and FX pass-through.
• If already long CPAY, sell upside calls against the position into the Corporate Payments presentation window to monetize elevated event premium while preserving upside through the presentation.
• Use the post-earnings reaction to add only if management reaffirms sustainable mid-teens organic growth; if that language softens, treat it as a signal to reduce exposure rather than average down.